Good evening :)
Switch to
Place Order

Eris Lifesciences Ltd

ERIS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹9,063 cr, stock is ranked 372
Low RiskStock is 1.43x as volatile as Nifty
669.600.47% (+3.10)
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹9,063 cr, stock is ranked 372
Low RiskStock is 1.43x as volatile as Nifty

Key Metrics

PE RatioPE RatioPB RatioPB RatioDividend YieldDiv. Yield
22.324.750.90%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
35.694.330.89%

Forecast & RatingsDetailed Forecast 

100%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Eris Lifesciences Limited is an India-based company that is primarily engaged in the manufacturing and marketing of pharmaceutical products. The Company’s manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals and nutrients (VMN). The Company's brands include Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Company’s wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited and Eris Healthcare Private Limited.

Investor PresentationView older 

Oct 20, 2022

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Financial TrendFinancial statements 

2019202020212022+1.01+1.09+1.22+1.37+0.29+0.30+0.36+0.41
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

General updates 
Announced OnNov 18, 2022

Eris Lifesciences Limited has informed the Exchange about SUBMISSION OF APPLICATION FOR RECLASSIFICATION | Download

Eris Lifesciences Limited has informed the Exchange about SUBMISSION OF APPLICATION FOR RECLASSIFICATION | Download

Schedule of Analysts/Institutional Investor Meet/Con. Call 
Announced OnNov 14, 2022

Eris Lifesciences Limited has informed the Exchange about Schedule of Analysts/Institutional Investor Meet/Con. Call | Download

Eris Lifesciences Limited has informed the Exchange about Schedule of Analysts/Institutional Investor Meet/Con. Call | Download

Cash Dividend 
Ex. DateAug 11, 2022

Interim • Div/Share: ₹ 7.35

See all events